Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

S6879

Sigma-Aldrich

D-Sphingosine

from bovine brain, ~99% (TLC)

Sinonimo/i:

(2S,3R,4E)-2-Amino-4-octadecene-1,3-diol, 4-Sphingenine, trans-D-erythro-2-Amino-4-octadecene-1,3-diol

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C18H37NO2
Numero CAS:
123-78-4
Peso molecolare:
299.49
Beilstein:
1727294
Numero CE:
204-651-3
Numero MDL:
MFCD00036751
Codice UNSPSC:
12352211
ID PubChem:
329824571

Origine biologica

bovine brain

Saggio

~99% (TLC)

Temperatura di conservazione

−20°C

Stringa SMILE

OC[C@@](N)([H])[C@]([H])(O)/C=C/CCCCCCCCCCCCC

InChI

1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)17(19)16-20/h14-15,17-18,20-21H,2-13,16,19H2,1H3/b15-14+/t17-,18+/m0/s1
WWUZIQQURGPMPG-KRWOKUGFSA-N

Informazioni sul gene

human ... PRKCA(5578) , PRKCB(5579) , PRKCD(5580) , PRKCE(5581) , PRKCG(5582) , PRKCH(5583) , PRKCI(5584)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

D-Sphingosine from bovine brain was tested for effects on distribution of clathrin/AP-2 in cultured fibroblasts.8 It was used to prepare vesicles and study the interactions of DNA with bilayers of cationic liposomes.9

Azioni biochim/fisiol

A constituent of cell membranes. Precursor of ceramide. Selective inhibitor of protein kinase C, but does not inhibit protein kinase A or myosin light chain kinase. Inhibitor of calmodulin-dependent enzymes.

Qualità

May contain small amounts of structural analogues.

Nota sulla preparazione

Prepared from sphingomyelin.

Prodotto comparabile

N° Catalogo
Descrizione
Determinazione del prezzo

S7049

D-Sphingosine, synthetic

Indicazioni di pericolo

H413

Consigli di prudenza

P273 - P501

Classi di pericolo

Aquatic Chronic 4

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Susan M Hancock et al.
Nature chemical biology, 5(7), 508-514 (2009-06-16)
Though glycosphingolipids have great potential as therapeutics for cancer, HIV, neurodegenerative diseases and auto-immune diseases, both extensive study of their biological roles and development as pharmaceuticals are limited by difficulties in their synthesis, especially on large scales. Here we addressed
Meret E Ricklin et al.
Neurology, 81(2), 174-181 (2013-05-24)
To study the immune response against varicella-zoster virus (VZV) in patients with multiple sclerosis before and during fingolimod therapy. The VZV-specific immune response was studied using interferon (IFN)-γ enzyme-linked immunosorbent spot assay, proliferation assays, and upregulation of T-cell activation markers
Mei-Hong Li et al.
Pediatric blood & cancer, 60(9), 1418-1423 (2013-05-25)
Neuroblastoma (NB) is the most common extra-cranial solid tumor in childhood. Poor outcomes for children with advanced disease underscore the need for novel therapeutic strategies. FTY720, an immunomodulating drug approved for multiple sclerosis, has been investigated in oncology with promising
Jeroen Tibboel et al.
Chest, 145(1), 120-128 (2014-01-08)
Sphingolipids comprise a class of bioactive lipids that are involved in a variety of pathophysiologic processes, including cell death and survival. Ceramide and sphingosine-1-phosphate (S1P) form the center of sphingolipid metabolism and determine proapoptotic and antiapoptotic balance. Findings in animal
Paolo Neviani et al.
The Journal of clinical investigation, 123(10), 4144-4157 (2013-09-04)
The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML) depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However, CML quiescent HSCs are TKI resistant and represent a BCR-ABL1 kinase-independent disease reservoir. Here we
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.